CTOs on the Move

NovoLogix(SM)

www.novologix.net

 
NovoLogix is a cutting-edge Medical Pharmacy Benefit Management company.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.novologix.net
  • 10400 Viking Drive, Suite 200
    Eden Prairie, MN USA 55344
  • Phone: 888.480.3972

Executives

Name Title Contact Details

Similar Companies

Indiana University Health

Established in 1997, the Indiana University Health family has grown to include an expanding network of partner hospitals across the state of Indiana. With several well-respected Centers of Excellence and a strong partnership with the Indiana University School of Medicine, IU Health is a leader in health care quality, medical innovation and patient satisfaction.

Department of Medical Assistance Services

The Department of Medical Assistance Services plays a critical role in providing health care coverage to low-income children, older adults, individuals with disabilities and pregnant women. There are nearly 400,000 uninsured Virginians eligible for new cost-effective health care options through the same modern and efficient management that is serving the Commonwealth well today

Danube Pharmaeuticals,

Danube Pharmaeuticals, Inc., is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hospice of Southern Maine

Calling Hospice of Southern Maine doesn`t mean you`re giving up, it means you`re taking charge. At Hospice of Southern Maine, our mission is to provide compassion, care and comfort through the end of life for patients with a terminal illnesses and their families. We care for patients where they are, whether at home, in a long-term care and assisted living center, or at Gosnell Memorial Hospice House, our 18-bed facility in Scarborough.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.